IL-17A is elevated in sera of patients with poorly differentiated ovarian papillary serous cystadenocarcinoma

Malekzadeh, Mahyar; Dehaghani, Alamtaj Samsami; Ghaderi, Abbas; Doroudchi, Mehrnoosh

doi:10.3233/cbm-140392

Cited by 4 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our best of knowledge, there is no report on the serum IL-17A levels in Fars province of Iran with a relatively high rate of gastric cancer. In the previous studies in this same area, we have observed a higher level of IL-17A in the sera of patients with colorectal (Nemati et al, 2015) as well as glioma, bladder and ovarian cancers (Doroudchi et al, 2013a;Doroudchi et al, 2013b;Malekzadeh et al, 2013). Therefore, in a preliminary study to evaluate the possible increase of IL-17A in the sera of GC patients in our area, we measured the IL-17A and its association with some clinicopathological factors in a group of Iranian patients with gastric cancer residing in Fars region.…”

Section: Il-17a Levels In the Sera Of Patients With Gastric Cancer Show Limited Elevationmentioning

confidence: 64%

IL-17A Levels in the Sera of Patients with Gastric Cancer Show Limited Elevation

Malek-Hosseini

Taherinejad²,

Malekzadeh³

et al. 2015

Asian Pacific Journal of Cancer Prevention

Self Cite

View full text Add to dashboard Cite

Background: Inflammation plays a major role in the development and progression of gastric and other gastrointestinal tumors. The IL-17 family of cytokines has been under investigation as targets of immunotherapy. Materials and Methods: We investigated the levels of IL-17A inflammatory cytokine in the sera of 57 patients with gastric cancer (GC) and 90 healthy age/sex matched controls using ELISA methods. Results: In only 5 (8.8%) of the patients' sera was IL-17A detectable. No IL-17A was apparent in the sera of healthy controls. The maximum concentration of IL-17A in patients was 7.004 pg/ml. Vascular and lymphatic invasions were only seen in one of the 5 positive cases. Although all of them were in the age group >60 years, no correlation was seen between age and IL-17A level. These results are somewhat different from our findings for colorectal cancer (CRC) in the same population. Conclusions: It is possible that the inflammopathology of CRC and GC are rather different, at least in Fars, a southern province of Iran.

show abstract

Section: Il-17a Levels In the Sera Of Patients With Gastric Cancer Show Limited Elevationmentioning

confidence: 64%

IL-17A Levels in the Sera of Patients with Gastric Cancer Show Limited Elevation

Malek-Hosseini

Taherinejad²,

Malekzadeh³

et al. 2015

Asian Pacific Journal of Cancer Prevention

Self Cite

View full text Add to dashboard Cite

show abstract

“…ey also observed a higher concentration of the assessed cytokine in the serum of patients with OC with a low degree of histological differentiation, compared to cancer with a high and medium degree of differentiation. According to them, this observation may suggest the existence of various sources of IL-17 ( 17 or cancer cells) involved in the production of this cytokine at particular stages of tumor progression [52]. Tang et al showed a higher level of IL-17 expression in the tissue of ovarian malignant tumors, compared to benign tumor tissue and controls.…”

Section: Controlmentioning

confidence: 99%

Th17 Cells and IL-17 As Novel Immune Targets in Ovarian Cancer Therapy

Bilska

Pawłowska

Zakrzewska³

et al. 2020

Journal of Oncology

View full text Add to dashboard Cite

Ovarian cancer (OC) is usually diagnosed at an advanced stage and is related with poor prognosis. Despite numerous studies, the pathogenesis of OC is still unknown. Recent studies indicate the role of the immune system in the development and spread of OC. The identification of factors and mechanisms involved in that process and their modulation is crucial for creating effective antitumor therapy. We investigated the potential role of Th17 cells in OC patients (n = 71) by analyzing the frequencies of Th17 cells in three different environments, i.e., peripheral blood (PB), peritoneal fluid (PF), and tissue (Th17 infiltrating cells), and the concentration of IL-17A in plasma and PF of patients in terms of their clinical and prognostic significance. Th17 cells were analyzed by flow cytometry as a percentage of CD4+ lymphocytes that expressed intracellular expression of IL-17A. The level of IL-17A in plasma and PF were determined by ELISA. Our results showed accumulation of Th17 cells among tumor-infiltrating CD4+ lymphocytes (p<0.001 in relation to PB). Moreover, the percentage of Th17 cells in both PB and PF of OC patients was significantly lower than that in benign tumors group (n = 35). There were no significant differences in the percentage of Th17 cells in PB, PF, and tissue in relation to clinicopathological characteristics of OC patients and survival. The lower percentage of Th17 cells in the PB and PF of OC patients may promote evasion of host immune response by cancer cells. The concentration of IL-17A in plasma of OC patients was higher (p<0.0001) than that in both benign tumors and control group (n = 10). The PF IL-17A level in OC patients was higher (p<0.0001) than that in women with benign ovarian tumors, indicating its synthesis in OC microenvironment. Higher IL-17A level in PF is correlated with longer (median: 36.5 vs. 27 months) survival of OC patients.

show abstract

Pro-inflammatory cytokines and CXC chemokines as game-changer in age-associated prostate cancer and ovarian cancer: Insights from preclinical and clinical studies' outcomes

Ullah,

Chen,

Singla

et al. 2024

Pharmacological Research

View full text Add to dashboard Cite

IL-17A is elevated in sera of patients with poorly differentiated ovarian papillary serous cystadenocarcinoma

Abstract: Elevation of IL-17A in a high percentage of ovarian serous cystadenocarcinoma and lack of this cytokine in healthy individuals makes it a specific candidate in diagnosis, follow up or immunotherapy.

Cited by 4 publications

References 39 publications

IL-17A Levels in the Sera of Patients with Gastric Cancer Show Limited Elevation

IL-17A Levels in the Sera of Patients with Gastric Cancer Show Limited Elevation

Th17 Cells and IL-17 As Novel Immune Targets in Ovarian Cancer Therapy

Pro-inflammatory cytokines and CXC chemokines as game-changer in age-associated prostate cancer and ovarian cancer: Insights from preclinical and clinical studies' outcomes

Contact Info

Product

Resources

About